$QNCX
Quince Therapeutics, Inc. Stock $qncx

$qncx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024039440 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.971M	$4.909M	$17.70M
YoY Change	29.79%	38.28%	-31.97%
% of Gross Profit
Research & Development	$3.702M	$3.434M	$9.447M
YoY Change	14.61%	23.97%	-62.48%
% of Gross Profit
Depreciation & Amortization	$40.00K	$302.0K	$300.0K
YoY Change	100.0%	655.0%	47.06%
% of Gross Profit
Operating Expenses	$11.22M	$9.921M	$34.62M
YoY Change	-13.41%	56.98%	-33.44%
Operating Profit	-$11.22M		-$34.62M
YoY Change	-13.41%		-33.44%
Interest Expense	$887.0K	$1.014M	$3.478M
YoY Change	26.71%	87.78%	225.05%
% of Operating Profit
Other Income/Expense, Net	-$399.0K	$64.00K	-$102.0K
YoY Change	62.2%	-74.4%	-89.77%
Pretax Income	-$11.12M	-$8.843M	-$31.58M
YoY Change	-11.06%	59.91%	-39.2%
Income Tax	$31.00K	$51.00K	$197.0K
% Of Pretax Income
Net Earnings	-$11.15M	-$8.894M	-$31.39M
YoY Change	-9.02%	60.83%	-39.25%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.26		-$0.84
Diluted Earnings Per Share	-$0.26	-$0.22	-$0.84
COMMON SHARES
Basic Shares Outstanding	43.22M	42.87M	37.24M
Diluted Shares Outstanding	43.01M		37.24M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$67.82M	$75.06M	$75.06M
YoY Change	-20.91%	-16.77%	-16.79%
Cash & Equivalents	$21.81M	$20.75M	$4.285M
Short-Term Investments	$46.01M	$54.31M	$69.25M
Other Short-Term Assets	$48.00K	$81.00K	$2.381M
YoY Change	-73.18%	-70.65%	-33.86%
Inventory
Prepaid Expenses	$342.0K	$365.0K
Receivables
Other Receivables
Total Short-Term Assets	$70.44M	$77.44M	$77.44M
YoY Change	-23.84%	-17.4%	-17.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$234.0K	$234.0K	$619.0K
YoY Change	3800.0%	-40.46%	-11.57%
Goodwill	$17.25M	$17.63M
YoY Change
Intangibles	$62.25M	$63.67M
YoY Change		979.19%
Long-Term Investments	$78.00K	$78.00K	$78.00K
YoY Change	-84.4%	-97.83%	-97.83%
Other Assets	$8.467M	$8.456M	$8.466M
YoY Change	8367.0%
Total Long-Term Assets	$88.85M	$90.46M	$90.46M
YoY Change	10644.01%	790.18%	786.86%
TOTAL ASSETS
Total Short-Term Assets	$70.44M	$77.44M	$77.44M
Total Long-Term Assets	$88.85M	$90.46M	$90.46M
Total Assets	$159.3M	$167.9M	$167.9M
YoY Change	70.7%	61.58%	61.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.070M	$2.033M	$2.033M
YoY Change	25.38%	256.67%	238.83%
Accrued Expenses	$3.020M	$3.436M	$3.436M
YoY Change	106.28%	37.49%	43.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$9.838M	$9.572M	$9.572M
YoY Change	215.83%	211.89%	208.77%
LONG-TERM LIABILITIES
Long-Term Debt	$13.52M	$13.43M	$13.43M
YoY Change
Other Long-Term Liabilities	$599.0K	$587.0K	$54.51M
YoY Change
Total Long-Term Liabilities	$599.0K	$587.0K	$67.94M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.838M	$9.572M	$9.572M
Total Long-Term Liabilities	$599.0K	$587.0K	$67.94M
Total Liabilities	$85.12M	$82.82M	$82.82M
YoY Change	2632.42%	2396.71%	2409.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$330.8M	-$319.6M
YoY Change	10.08%	10.86%
Common Stock	$403.1M	$6.500M
YoY Change	3.19%	-98.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.18M	$85.08M	$85.08M
YoY Change
Total Liabilities & Shareholders Equity	$159.3M	$167.9M	$167.9M
YoY Change	70.7%	61.58%	61.6%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.15M	-$8.894M	-$31.39M
YoY Change	-9.02%	60.83%	-39.25%
Depreciation, Depletion And Amortization	$40.00K	$302.0K	$300.0K
YoY Change	100.0%	655.0%	47.06%
Cash From Operating Activities	-$8.353M	-$6.082M	-$18.29M
YoY Change	134.04%	4.14%	-58.46%
INVESTING ACTIVITIES
Capital Expenditures	$39.00K	$20.00K	$160.0K
YoY Change	-71.32%	-71.43%	20.3%
Acquisitions
YoY Change
Other Investing Activities	$8.953M	$5.412M	-$5.598M
YoY Change	57.62%	-71.14%	-130.86%
Cash From Investing Activities	$8.914M	$5.392M	-$5.758M
YoY Change	60.9%	-71.1%	-131.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	190.0K	53.00K	143.0K
YoY Change	280.0%	-365.0%	-79.77%
NET CHANGE
Cash From Operating Activities	-8.353M	-6.082M	-18.29M
Cash From Investing Activities	8.914M	5.392M	-5.758M
Cash From Financing Activities	190.0K	53.00K	143.0K
Net Change In Cash	1.061M	-637.0K	-23.83M
YoY Change	-50.3%	-104.98%	-5.24%
FREE CASH FLOW
Cash From Operating Activities	-$8.353M	-$6.082M	-$18.29M
Capital Expenditures	$39.00K	$20.00K	$160.0K
Free Cash Flow	-$8.392M	-$6.102M	-$18.45M
YoY Change	126.5%	3.25%	-58.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	http://fasb.org/us-gaap/2023#QualifiedPlanMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38890
CY2023	dei	Entity Registrant Name EntityRegistrantName	Quince Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-1024039
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	611 Gateway Boulevard, Suite 273
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001662774
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023	dei	City Area Code CityAreaCode	415
CY2023	dei	Local Phone Number LocalPhoneNumber	910-5717
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	50000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43215233
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20752000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44579000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	54307000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	45602000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2381000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3567000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	77440000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	93748000
CY2023Q4	qncx	Assets Held For Sale Not Part Of Disposal Group Non Current AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent	10000
CY2022Q4	qncx	Assets Held For Sale Not Part Of Disposal Group Non Current AssetsHeldForSaleNotPartOfDisposalGroupNonCurrent	0
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	234000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	393000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	385000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	291000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	3578000
CY2023Q4	us-gaap	Goodwill Goodwill	17625000
CY2022Q4	us-gaap	Goodwill Goodwill	0
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	63672000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5900000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8456000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2023Q4	qncx	Equity Investments In Lighthouse Inc EquityInvestmentsInLighthouseInc	78000
CY2022Q4	qncx	Equity Investments In Lighthouse Inc EquityInvestmentsInLighthouseInc	0
CY2023Q4	us-gaap	Assets Assets	167900000
CY2022Q4	us-gaap	Assets Assets	103910000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2033000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	570000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4103000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3436000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2499000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9572000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3069000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	13429000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	321000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	53603000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5304000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	248000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	587000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2023Q4	us-gaap	Liabilities Liabilities	82816000
CY2022Q4	us-gaap	Liabilities Liabilities	3317000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42973215
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42973215
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36136480
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36136480
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	43000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	36000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	401638000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	389105000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3047000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-289000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319644000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288259000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	85084000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100593000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167900000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103910000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9447000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25178000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17695000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26012000
CY2023	qncx	Goodwill Impairment Charge GoodwillImpairmentCharge	0
CY2022	qncx	Goodwill Impairment Charge GoodwillImpairmentCharge	825000
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	5900000
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023	qncx	Fair Value Adjustment For Contingent Consideration FairValueAdjustmentForContingentConsideration	1578000
CY2022	qncx	Fair Value Adjustment For Contingent Consideration FairValueAdjustmentForContingentConsideration	0
CY2023	us-gaap	Operating Expenses OperatingExpenses	34620000
CY2022	us-gaap	Operating Expenses OperatingExpenses	52015000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-34620000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-52015000
CY2023	qncx	Fair Value Adjustment For Long Term Debt FairValueAdjustmentForLongTermDebt	338000
CY2022	qncx	Fair Value Adjustment For Long Term Debt FairValueAdjustmentForLongTermDebt	0
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3478000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1068000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-102000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-997000
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-31582000
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-51944000
CY2023	qncx	Income Tax Benefit IncomeTaxBenefit	-197000
CY2022	qncx	Income Tax Benefit IncomeTaxBenefit	-284000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31385000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-51660000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2789000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	248000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	547000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-458000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28049000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51870000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37237149
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37237149
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33496534
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33496534
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	118586000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	608000
CY2022	qncx	Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod	148000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16618000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	16503000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	248000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-458000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-51660000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100593000
CY2023	qncx	Share Based Compensation Arrangement By Share Based Payment Award Value Options And Non Option Equity Instruments Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod	167000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	18000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5220000
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7171000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2789000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	547000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31385000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	85084000
CY2023	us-gaap	Profit Loss ProfitLoss	-31385000
CY2022	us-gaap	Profit Loss ProfitLoss	-51660000
CY2023	qncx	Non Cash Rent Expense NonCashRentExpense	0
CY2022	qncx	Non Cash Rent Expense NonCashRentExpense	-29000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5220000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16618000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	322000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	204000
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	66000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	136000
CY2023	qncx	Gain On Sale Of Legacy Assets GainOnSaleOfLegacyAssets	78000
CY2022	qncx	Gain On Sale Of Legacy Assets GainOnSaleOfLegacyAssets	0
CY2023	qncx	Loss On Disposal LossOnDisposal	37000
CY2022	qncx	Loss On Disposal LossOnDisposal	94000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1578000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2023	qncx	Increase Decrease In Fair Value Of Borrowings IncreaseDecreaseInFairValueOfBorrowings	338000
CY2022	qncx	Increase Decrease In Fair Value Of Borrowings IncreaseDecreaseInFairValueOfBorrowings	0
CY2023	qncx	Non Cash Goodwill Impairment Charge NonCashGoodwillImpairmentCharge	0
CY2022	qncx	Non Cash Goodwill Impairment Charge NonCashGoodwillImpairmentCharge	825000
CY2023	qncx	Non Cash Intangible Impairment Charge NonCashIntangibleImpairmentCharge	5900000
CY2022	qncx	Non Cash Intangible Impairment Charge NonCashIntangibleImpairmentCharge	0
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2019000
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	113000
CY2023	qncx	Change In Deferred Tax Liabilities Due To Acquisition ChangeInDeferredTaxLiabilitiesDueToAcquisition	248000
CY2022	qncx	Change In Deferred Tax Liabilities Due To Acquisition ChangeInDeferredTaxLiabilitiesDueToAcquisition	284000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4246000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2580000
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	9000
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-194000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-288000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5943000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1972000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6660000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18292000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44038000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	113781000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	75021000
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	111209000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	82493000
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	10593000
CY2023	qncx	Advancement Of Notes Receivable AdvancementOfNotesReceivable	1000000
CY2022	qncx	Advancement Of Notes Receivable AdvancementOfNotesReceivable	0
CY2023	qncx	Cash Paid In Acquisition For Business Net Of Cash Acquired CashPaidInAcquisitionForBusinessNetOfCashAcquired	2116000
CY2022	qncx	Cash Paid In Acquisition For Business Net Of Cash Acquired CashPaidInAcquisitionForBusinessNetOfCashAcquired	0
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	90000
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	70000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	160000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5758000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18002000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	6000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	49000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	149000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	148000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	608000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	707000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23827000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25145000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44579000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69724000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20752000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44579000
CY2023	qncx	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities1 RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities1	0
CY2022	qncx	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities1 RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities1	411000
CY2023	qncx	Right Of Use Asset And Financing Lease Liability Reduction As A Result Of Lease Modification RightOfUseAssetAndFinancingLeaseLiabilityReductionAsAResultOfLeaseModification	-70000
CY2022	qncx	Right Of Use Asset And Financing Lease Liability Reduction As A Result Of Lease Modification RightOfUseAssetAndFinancingLeaseLiabilityReductionAsAResultOfLeaseModification	0
CY2023	qncx	Right Of Use Asset And Operating Lease Liability Reduction As A Result Of Lease Modification RightOfUseAssetAndOperatingLeaseLiabilityReductionAsAResultOfLeaseModification	0
CY2022	qncx	Right Of Use Asset And Operating Lease Liability Reduction As A Result Of Lease Modification RightOfUseAssetAndOperatingLeaseLiabilityReductionAsAResultOfLeaseModification	-640000
CY2023	qncx	Entity Date Of Incorporation EntityDateOfIncorporation	2012-06
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319600000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	75100000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company’s consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with the acquisition of Novosteo, Inc. and EryDel S.p.A., including associated intangible assets and goodwill, contingent consideration, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets or goodwill; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company’s estimates.</span></p>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, repurchase agreements, treasury bills and notes, government bonds, and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, cash balances in excess of Federal Deposit Insurance Corporation (FDIC) insured limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million are at risk.</span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	300000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	100000
CY2023Q4	qncx	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2023Q4	qncx	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2022Q4	qncx	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2022Q4	qncx	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73538000
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	71135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	89773000
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20752000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	44579000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	54307000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	45602000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	3578000
CY2023	qncx	Weighted Average Remaining Contractual Maturities Of Available For Sale Securities WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities	P2M
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	73548000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	23000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73538000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	19231000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	54307000
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	73538000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	90330000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	562000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	89773000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	40593000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	45602000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	3578000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	89773000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	3966000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	3704000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	23000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	7670000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	23000
CY2023Q4	qncx	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2023Q4	qncx	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022Q4	qncx	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	54307000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	54307000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	365000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	223000
CY2023Q4	qncx	Prepaid Insurance Current PrepaidInsuranceCurrent	809000
CY2022Q4	qncx	Prepaid Insurance Current PrepaidInsuranceCurrent	977000
CY2023Q4	qncx	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	133000
CY2022Q4	qncx	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	1088000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	81000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	276000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2381000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3567000
CY2023Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	3463000
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	0
CY2023Q4	us-gaap	Other Assets OtherAssets	8456000
CY2022Q4	us-gaap	Other Assets OtherAssets	0
CY2023Q4	qncx	Assets Held For Sale AssetsHeldForSale	10000
CY2022Q4	qncx	Assets Held For Sale AssetsHeldForSale	0
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	507000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	185000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	234000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	393000
CY2023	us-gaap	Depreciation Depreciation	300000
CY2022	us-gaap	Depreciation Depreciation	200000
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	2340000
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1130000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	211000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	234000
CY2023Q4	qncx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	564000
CY2022Q4	qncx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	497000
CY2023Q4	qncx	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	64000
CY2022Q4	qncx	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	377000
CY2023Q4	qncx	Accrued Finance Lease Liabilities Current AccruedFinanceLeaseLiabilitiesCurrent	0
CY2022Q4	qncx	Accrued Finance Lease Liabilities Current AccruedFinanceLeaseLiabilitiesCurrent	-76000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	257000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	185000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3436000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2499000
CY2022Q4	qncx	Accrued Severance AccruedSeverance	0
CY2021Q4	qncx	Accrued Severance AccruedSeverance	0
CY2023	qncx	Accrued Severance Incurred AccruedSeveranceIncurred	770000
CY2022	qncx	Accrued Severance Incurred AccruedSeveranceIncurred	3942000
CY2023	qncx	Accrued Severance Paid AccruedSeverancePaid	-429000
CY2022	qncx	Accrued Severance Paid AccruedSeverancePaid	-3942000
CY2023Q4	qncx	Accrued Severance AccruedSeverance	341000
CY2022Q4	qncx	Accrued Severance AccruedSeverance	0
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	300000
CY2023	us-gaap	Other Restructuring Costs OtherRestructuringCosts	100000
CY2023Q3	us-gaap	Severance Costs1 SeveranceCosts1	500000
CY2023	qncx	Severance Costs Recognized SeveranceCostsRecognized	100000
CY2023Q3	qncx	Additional Cash Bonous Severance Percentage AdditionalCashBonousSeverancePercentage	1
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.50
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	266000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	572000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	96000
CY2023	qncx	Operating Lease Future Rent Expense OperatingLeaseFutureRentExpense	400000
CY2023	qncx	Finance Lease Amortized Period On Equipment Service FinanceLeaseAmortizedPeriodOnEquipmentService	P18M
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	50000
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	70000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	385000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	291000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	64000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	377000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	321000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	385000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	377000
CY2023Q4	qncx	Finance Lease Right Of Use Asset Gross FinanceLeaseRightOfUseAssetGross	0
CY2022Q4	qncx	Finance Lease Right Of Use Asset Gross FinanceLeaseRightOfUseAssetGross	124000
CY2023Q4	qncx	Accumulated Amortization Of Finance Lease AccumulatedAmortizationOfFinanceLease	0
CY2022Q4	qncx	Accumulated Amortization Of Finance Lease AccumulatedAmortizationOfFinanceLease	50000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	74000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0795
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0571
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0445
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	91000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	91000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	88000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	81000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	69000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	48000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	469000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	385000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	50000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	75000
CY2023	us-gaap	Lease Cost LeaseCost	368000
CY2022	us-gaap	Lease Cost LeaseCost	697000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11053000
CY2023Q4	qncx	Long Term Debt Maturities Repayments Of Principal Year Four And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter	0
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	11053000
CY2023Q4	qncx	Debt Instrument Imputed Interest DebtInstrumentImputedInterest	2376000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	13429000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	300000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1400000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.82
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11100000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	31800000
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4000000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M18D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5220000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16618000
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14324720
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12745170
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock is entitled to one vote
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42973215
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42973215
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36136480
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36136480
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-27375000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-48191000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4207000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3753000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31582000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-51944000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	61000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	61000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-248000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	284000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-10000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-258000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	284000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	197000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-284000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0447
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0089
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0107
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0149
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.2635
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0082
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0125
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0338
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0168
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1863
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0062
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0055
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	81881000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	49481000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2401000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9667000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	527000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	515000
CY2023Q4	qncx	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Capitalized Research And Development Expense DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizedResearchAndDevelopmentExpense	3220000
CY2022Q4	qncx	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Capitalized Research And Development Expense DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizedResearchAndDevelopmentExpense	3094000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	8343000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7970000
CY2023Q4	qncx	Deferred Tax Asset Disallowed Interest Expense Carryforwards DeferredTaxAssetDisallowedInterestExpenseCarryforwards	1043000
CY2022Q4	qncx	Deferred Tax Asset Disallowed Interest Expense Carryforwards DeferredTaxAssetDisallowedInterestExpenseCarryforwards	0
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	97415000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70727000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85111000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	69692000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12304000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1035000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	11000
CY2023Q4	qncx	Deferred Tax Liabilities Capitalized Leases DeferredTaxLiabilitiesCapitalizedLeases	0
CY2022Q4	qncx	Deferred Tax Liabilities Capitalized Leases DeferredTaxLiabilitiesCapitalizedLeases	32000
CY2023Q4	qncx	Deferred Tax Liabilities Research And Development In Process DeferredTaxLiabilitiesResearchAndDevelopmentInProcess	17608000
CY2022Q4	qncx	Deferred Tax Liabilities Research And Development In Process DeferredTaxLiabilitiesResearchAndDevelopmentInProcess	1239000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17608000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1282000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5304000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	247000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15400000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11100000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	500000
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	100000
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3688000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3249000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	200000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	451000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	439000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4339000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3688000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31385000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-51660000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37237149
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37237149
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33496534
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33496534
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7088167
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8023348
CY2023	qncx	Defined Contribution Plan Name DefinedContributionPlanName	401(k)
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200
CY2023Q4	qncx	Nda Acceptance Under Contigent Consideration NdaAcceptanceUnderContigentConsideration	25000000
CY2023Q4	qncx	Probability Discount Rate Of Each Milestone ProbabilityDiscountRateOfEachMilestone	0.15
CY2023	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2500000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	10593000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1040000
CY2022Q2	qncx	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets	124000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	279000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	5900000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	1726000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	532000
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	15678000
CY2022Q2	us-gaap	Goodwill Goodwill	825000
CY2023	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	0
CY2022	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	0
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	262000
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-52592000
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2200000
CY2021Q4	us-gaap	Goodwill Goodwill	0
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	825000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	825000
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	16929000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	696000
CY2023Q4	us-gaap	Goodwill Goodwill	17625000

Files In Submission

Name	View Source	Status
0000950170-24-039440-index-headers.html	Edgar Link	pending
0000950170-24-039440-index.html	Edgar Link	pending
0000950170-24-039440.txt	Edgar Link	pending
0000950170-24-039440-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img175013337_0.jpg	Edgar Link	pending
img175013337_1.jpg	Edgar Link	pending
img175013337_2.jpg	Edgar Link	pending
img175013337_3.jpg	Edgar Link	pending
img175013337_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qncx-20231231.htm	Edgar Link	pending
qncx-20231231.xsd	Edgar Link	pending
qncx-ex10_26.htm	Edgar Link	pending
qncx-ex10_27.htm	Edgar Link	pending
qncx-ex10_6.htm	Edgar Link	pending
qncx-ex21_1.htm	Edgar Link	pending
qncx-ex23_1.htm	Edgar Link	pending
qncx-ex31_1.htm	Edgar Link	pending
qncx-ex31_2.htm	Edgar Link	pending
qncx-ex32_1.htm	Edgar Link	pending
qncx-ex32_2.htm	Edgar Link	pending
qncx-ex97_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qncx-20231231_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QNCX
Quince Therapeutics, Inc. Stock $qncx

2024 Q1 Form 10-K Financial Statement

#000095017024039440 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QNCX Quince Therapeutics, Inc. Stock $qncx

2024 Q1 Form 10-K Financial Statement

#000095017024039440 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QNCX
Quince Therapeutics, Inc. Stock $qncx